Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
10757543 | Biochemical and Biophysical Research Communications | 2013 | 6 Pages |
Abstract
ATG4B belongs to the autophagin family of cysteine proteases required for autophagy, an emerging target of cancer therapy. Developing pharmacological ATG4B inhibitors is a very active area of research. However, detailed studies on the role of ATG4B during anticancer therapy are lacking. By analyzing PC-3 and C4-2 prostate cancer cells overexpressing dominant negative ATG4BC74Ain vitro and in vivo, we show that the effects of ATG4BC74A are cell type, treatment, and context-dependent. ATG4BC74A expression can either amplify the effects of cytotoxic therapies or contribute to treatment resistance. Thus, the successful clinical application of ATG4B inhibitors will depend on finding predictive markers of response.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Biochemistry
Authors
Elisa Tran, Annabelle Chow, Takeshi Goda, Amy Wong, Kim Blakely, Michelle Rocha, Samira Taeb, Van C. Hoang, Stanley K. Liu, Urban Emmenegger,